LifeNet Health Receives FDA Clearance for New Cardiovascular Technology

November 3, 2008 - LifeNet Health received 510(k) clearance from the FDA for CardioGraft allograft cardiac patch products with MatrACELL decellularization technology.

LifeNet Health received clearance for the technology for cardiac products, which safely removes donor cells from cardiovascular tissues while retaining the native biomechanical strength of the tissue.

The company said the clearance strengthens LifeNet Health’s position in the pediatric cardiac reconstruction market.

LifeNet Health, founded in 1982, is a full-service biomedical tissue banking system and a leading non-profit organ and tissue donation agency. It provides recovery and processing services for musculoskeletal and cardiovascular tissues, distributing more than 250,000 biomedical implants every year to restore health to patients around the world.

For more information: www.lifenethealth.org